Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2025)

Contineum Therapeutics has reported Accumulated Expenses over the past 3 years, most recently at $2.8 million for Q3 2025.

  • Quarterly results put Accumulated Expenses at $2.8 million for Q3 2025, up 29.26% from a year ago — trailing twelve months through Sep 2025 was $2.8 million (up 29.26% YoY), and the annual figure for FY2024 was $6.7 million, up 252.47%.
  • Accumulated Expenses for Q3 2025 was $2.8 million at Contineum Therapeutics, down from $3.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CTNM hit a ceiling of $6.7 million in Q4 2024 and a floor of $1.4 million in Q2 2024.
  • Median Accumulated Expenses over the past 3 years was $3.3 million (2025), compared with a mean of $3.5 million.
  • Biggest five-year swings in Accumulated Expenses: soared 252.47% in 2024 and later dropped 25.84% in 2025.
  • Contineum Therapeutics' Accumulated Expenses stood at $1.9 million in 2023, then soared by 252.47% to $6.7 million in 2024, then plummeted by 58.07% to $2.8 million in 2025.
  • The last three reported values for Accumulated Expenses were $2.8 million (Q3 2025), $3.7 million (Q2 2025), and $3.8 million (Q1 2025) per Business Quant data.